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Objective. In addition to the long-established
link with smoking, periodontitis (PD) is a risk factor
for rheumatoid arthritis (RA). This study was under-
taken to elucidate the mechanism by which PD could
induce antibodies to citrullinated peptides (ACPAs), by
examining the antibody response to a novel citrulli-
nated peptide of cytokeratin 13 (CK-13) identified in
gingival crevicular fluid (GCF), and comparing the
response to 4 other citrullinated peptides in patients
with RA who were well-characterized for PD and
smoking.
Methods. The citrullinomes of GCF and peri-
odontal tissue from patients with PD were mapped by
mass spectrometry. ACPAs of CK13 (cCK13), tenascin-C
(cTNC5), vimentin (cVIM), a-enolase (CEP-1), and
fibrinogen b (cFIBb) were examined by enzyme-linked
immunosorbent assay in patients with RA (n = 287)
and patients with osteoarthritis (n = 330), and cross-
reactivity was assessed by inhibition assays.
Results. A novel citrullinated peptide cCK13-1
(444TSNASGR-Cit-TSDV-Cit-RP458) identified in GCF
exhibited elevated antibody responses in RA patients
(24%). Anti–cCK13-1 antibody levels correlated with
anti–cTNC5 antibody levels, and absorption experi-
ments confirmed this was not due to cross-reactivity.
Only anti–cCK13-1 and anti-cTNC5 were associated
with antibodies to the periodontal pathogen Prevotella
intermedia (P = 0.05 and P = 0.001, respectively), but
not with antibodies to Porphyromonas gingivalis argi-
nine gingipains. Levels of antibodies to CEP-1, cFIBb,
and cVIM correlated with each other, and with smok-
ing and shared epitope risk factors in RA.
Conclusion. This study identifies 2 groups of
ACPA fine specificities associated with different RA
risk factors. One is predominantly linked to smoking
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and shared epitope, and the other links anti–cTNC5
and cCK13-1 to infection with the periodontal patho-
gen P intermedia.
Rheumatoid arthritis (RA) is an autoimmune
disease characterized by the generation of disease-spe-
cific autoantibodies against modified protein antigens
(1–3). The best-studied autoantibodies in RA to date
are those that recognize citrullinated peptides, whose
epitopes are created by the posttranslational conversion
of arginine residues to citrulline residues by peptidyl-
arginine deiminases (PADs). Among an increasing
number of citrullinated proteins identified as antigens
for autoantibodies in RA, peptides of citrullinated fi-
brinogen b (cFIBb) (4), citrullinated vimentin (cVIM)
(5), citrullinated a-enolase peptide 1 (CEP-1) (6), and
citrullinated tenascin-C (cTNC5) (7) are well character-
ized, and have been confirmed as diagnostically sensi-
tive and specific in independent cohorts.
Despite the fact that anti–citrullinated peptide
antibodies (ACPAs) are excellent biomarkers for RA
and widely used in disease diagnosis (8), it is still not
clear what triggers their production and how this
breach of tolerance occurs, nor is the contribution of
these autoantibodies to disease pathogenesis com-
pletely understood (9). The fact that ACPAs can be
detected years before any overt clinical symptoms of
RA (10), together with the association of RA with risk
factors including smoking (11) and periodontitis (PD)
(12), raises the possibility that these antibodies arise
due to events outside the joints, for example in the
lungs or periodontium.
PD is a chronic inflammatory disease of the
periodontium, characterized by the destruction of both
soft and hard tissue, and, ultimately, tooth loss. It is
associated with pathogen invasion of periodontal pock-
ets, creating a shift in the oral microbiota from a sym-
biotic to a dysbiotic community. Among these dysbiotic
species, an increased frequency of Porphyromonas gingi-
valis, a key PD-associated pathogen, is accompanied by
elevated levels of many other diverse species that are
also linked to PD, including Prevotella intermedia and
Fusobacterium nucleatum (13).
Citrullination has been observed in gingival tissue
from patients with PD by staining with pan–anticitrulline-
specific antibodies (14,15), and citrulline levels are ele-
vated in gingival crevicular fluid (GCF) samples from PD
patients (16). In a recent study, Konig et al (17) demon-
strated by mass spectrometry that a wide range of pro-
teins were citrullinated in GCF from patients with PD,
compared to minimal citrullination in subjects without
PD. However, that study did not examine the antibody
response to citrullinated GCF proteins, and whether this
could be related to PD in patients with RA. Citrullination
in PD may be mediated by endogenous human PAD or
by a bacterial PAD (PPAD) specifically expressed by P
gingivalis. PPAD preferentially citrullinates C-terminal
arginines exposed by the action of the bacterial gingipain
proteases (R gingipain type A [RgpA] and RgpB) that
cleave both bacterial and host proteins in PD tissue
(18,19). Taken together, these data suggest a causal link
between RA and PD, wherein citrullinated proteins gen-
erated in the periodontium may provide a primary source
of autoantibody epitopes that play a role in the initiation
of RA (20).
To further investigate the possibility that citrulli-
nation of proteins in PD contributes to the autoantibody
response in RA, we analyzed GCF and periodontal tis-
sues from patients with PD by mass spectrometry. Within
the periodontal citrullinome, we found citrullinated pro-
teins previously known to be targets of ACPAs in RA.
We also detected novel citrullinated sites, among which
was a peptide of cytokeratin 13 (cCK13-1). By comparing
antibody responses to this novel peptide and 4 other
well-established ACPA antigens, we identified distinct
patient subsets, each with different links to different RA
risk factors.
PATIENTS AND METHODS
Subjects. GCF was obtained from a total of 8 study
participants, including 2 controls without RA or PD, 3
patients with both RA and PD, 2 patients with PD but not
RA, and 1 patient with RA but not PD (16). Multiple peri-
odontal tissue samples were collected from a single PD
patient undergoing dental extraction, with informed consent
and ethical approval. Tissue samples were washed with sterile
phosphate buffered saline immediately after collection and
snap-frozen. No tissue was available from healthy subjects
because of ethical considerations.
The cohort used to analyze the antibody response to
citrullinated peptides has been described in detail previously
(12). This cohort comprises serum from 617 study partici-
pants, including 287 RA patients (100 patients with PD) and
330 osteoarthritis (OA) patients (87 patients with PD). RA
patients in this study had established disease with a mean dis-
ease duration exceeding 10 years. A vast majority had
received disease-modifying therapies including, but not lim-
ited to, methotrexate (62%), glucocorticoids (30%), and/or
biologic agents (31%). Serum samples from a separate group
of RA patients were used to analyze cross-reactivity (6). All
RA cases fulfilled the American College of Rheumatology
1987 classification criteria (21). PD was defined a priori
according to the definition of Machtei et al as the presence
of clinical attachment loss ≥6 mm on ≥2 teeth and ≥1 sites
with probing depths ≥5 mm (22). This definition equates clo-
sely to the US Centers for Disease Control and Prevention/
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American Academy of Periodontology case definition for
“severe” PD (23,24). Of those classified as having PD,
approximately one-fourth reported having prior periodontal
treatment and 16% reported prior periodontal surgery, with
frequencies that were similar in cases and controls (25).
Genotyping for the HLA–DRB1 shared epitope and
enzyme-linked immunosorbent assays (ELISAs) to measure
IgG antibody responses to outer membrane antigens of P gin-
givalis, P intermedia, and F nucleatum are described in detail
in the study by Mikuls et al (12). Nested polymerase chain
reaction (PCR) was used for the detection of P gingivalis in
subgingival plaque samples (26).
Liquid chromatography mass spectrometry/mass
spectrometry (LC-MS/MS) analyses of GCF and PD tissue.
GCF and PD tissue samples were stored at 80°C. GCF was
prepared for LC-MS/MS analysis as described previously (27).
Briefly, GCF was reduced and alkylated with dithiothreitol/
iodoacetamide, followed by protein precipitation using
chloroform and methanol. The protein pellet was solubilized
in 6M urea, diluted to 1M urea with ammonium bicarbonate,
digested with trypsin, and desalted on reverse-phase material
(Sola C18; Thermo Fisher).
Inflammatory gingival tissue surrounding the tooth
and subgingival plaque from root planing of the extracted
tooth was first lysed using Precellys bead beating (Bertin
Instruments) in radioimmunoprecipitation assay buffer (6,500
revolutions per minute for 40 seconds, followed by resting for
5 minutes on ice, repeated 3 times), followed by centrifuga-
tion at 15,000 rpm in the cold. The supernatant was prepared
for LC-MS/MS analysis as described above.
GCF and gingival tissue samples were analyzed on an
LC-MS/MS workflow comprising a Dionex Ultimate 3000
nLC system coupled to a Q-Exactive mass spectrometer
(Thermo Scientific) (28). Briefly, chromatographic separation
was achieved using a 50 cm nEASY spray column (PepMAP
C18; 75 lm 9 500 mm, 2 lm particle size) (Thermo Scien-
tific) and a linear acetonitrile gradient from 235% in 5%
DMSO and 0.1% formic acid. Precursor peptides were
detected with a resolution of 70,000 at 200 mass/charge fol-
lowed by the selection of up to 15 precursor ions. Raw data
were imported into Progenesis QI V4.1.4832.42146 (Waters)
for label-free quantitation and alignment, and peptides were
identified with PEAKS, version 7 (Bioinformatics Solutions).
Validation of citrullinated peptides. MS/MS spectra
were validated manually. We confirmed whether retention
times were altered if a noncitrullinated version of the peptide
was detected. We also made sure that the precursor selection
assigned the correct precursor mass and not the 13C peak.
This was repeated for all assigned fragment ions in the corre-
sponding MS/MS spectra as well. In addition, we shortlisted
citrullinated peptides with missed cleavage sites in the tryptic
digests. Deamidation was excluded by the assignment of site-
specific fragment ions.
We identified 756 protein groups in PD tissue sample
1 with 4,748 peptide sequences (peptide and protein false dis-
covery rate [FDR] 1%). In PD tissue sample 2 we found 242
protein groups with 2,476 sequences (FDR 1% for peptides
and 1.5% for proteins). GCF analysis resulted in the identifi-
cation of a total of 387 protein groups (FDR 1%) with 3,798
peptide sequences (FDR 1%).
Peptides and protein. Sera were tested for antibodies
to immunodominant peptides of cTNC5 (7), cVIM (5), cFIBb
(29), and CEP-1 (6) as well as antibodies to peptides of
cCK13 (accession number NP_002265.2). Peptides were syn-
thesized at a purity of >90%, with C-terminal and N-terminal
cysteines to facilitate cyclization (Pepceuticals) and solubilized
in water at 10 mg/ml. RgpB-6xHis was purified as previously
described (30).
ELISAs for citrullinated peptides and RgpB. ACPAs
were measured using a second-generation anti–cyclic citrulli-
nated peptide 2 (anti–CCP-2) IgG ELISA (Diastat; Axis-
Shield). ELISAs were used to detect antibodies against citrul-
linated peptides in human sera as previously described (6).
Briefly, 96-well plates were coated with 10 lg/ml peptide (or
5 lg/ml RgpB) (31), blocked with 2% bovine serum albumin,
and incubated with sera diluted 1:100. Bound antibodies were
detected with a horseradish peroxidase–conjugated anti-
human IgGFc monoclonal antibody (Stratech). A standard
curve of positive sera was used to calculate relative antibody
titers in arbitrary units for each sample for each peptide.
Anti-RgpB levels were expressed as optical density since the
assay was carried out without a standard curve; however, a
positive control on each plate gave a coefficient of variance
of <15% between plates. Inhibition ELISAs to analyze cross-
reactivity between ACPAs and citrullinated peptides were per-
formed as described previously (7).
Statistical analysis. CCP-2 serum positivity was
defined as a level of ≥5 units/ml. The 98th percentile in OA
control samples was used to define the cutoff for positive
antibody levels. Correlations between antibody levels were
calculated using Spearman’s rank correlation.
Chi-square tests were used to compare frequency dis-
tributions of categorical variables while t-tests and Wilcoxon’s
rank sum tests were used to compare all continuous variables.
Fisher’s exact tests were used in place of chi-square tests for
the CCP-2 analysis because of the small number of seronega-
tive cases. Venn analysis was conducted using the Venn Dia-
gram Generator (http://www.pangloss.com/seidel/Protocols/
venn.cgi) followed by proportional visualization with Venn
Diagram Plotter (by Kyle Littlefield and Matthew Monroe,
PNNL, Richland, WA).
RESULTS
Citrullinated proteins in GCF and periodontal
tissue. We identified 24 citrullinated peptides of 8 pro-
teins in GCF (Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40227/abstract) and 92 citrulli-
nated peptides of 56 proteins in PD tissue (Supplemen-
tary Table 2, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40227/abstract). In GCF, citrullinated peptides were
detected in samples from patients with both PD and
RA, but also in samples from patients with RA or PD
alone, and in samples from healthy controls. A number
of the citrullinated sites that we identified in this
study have previously been identified in RA synovial
tissue or fluid, and demonstrated to act as autoantigen
epitopes, including R35 in fibrinogen a (32), R715 in
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a2-macroglobulin, R450 and R304 in vimentin, R93 in
histone H2B type 2-E (33), R4 in histone 2A (34), as
well as R69 and R71 in vimentin (29). We also
detected citrullinated peptides in GCF and periodontal
tissues that have not been described as autoantigens in
RA. Noteworthy were a number of peptides of CK-13,
which were detected in 7 of the 8 GCF samples exam-
ined, but not in the tissue sample (Table 1 and Supple-
mentary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.c
om/doi/10.1002/art.40227/abstract). These data demon-
strate that citrullinated peptides are present in GCF
and in periodontal tissue from a patient with PD.
Peptide cCK13-1 is a novel peptide recognized
by ACPAs in patients with RA. CK-13 expression is
restricted to mucosal membranes. This specific localiza-
tion, combined with the high number of citrullinated
peptides identified in the C-terminal region of this pro-
tein, and the enrichment of these peptides in patients
with PD (Table 1 and Supplementary Figure 1), indi-
cated this as a good candidate for further examination.
We synthesized 2 CK-13 peptides with citrullines at
positions 451 and 456 (cCK13-1: 444TSNASGR-
cit-TSDV-cit-RP458), or at positions 451 and 457
(cCK13-2: 444TSNASGR-cit-TSDVR-cit-P458), and mapped
antibody responses to these peptides in a US cohort of
287 RA patients and 330 OA controls. Antibodies to
cCK13-1 had a diagnostic sensitivity of 24% and specificity
of 98% in RA, while no antibodies were detected
against cCK13-2 (Table 2) or against arginine control pep-
tides (data not shown). Taken together, these data indicate
that an antibody response in RA exists toward a citrulli-
nated epitope that can be generated in inflamed periodon-
tal tissue.
Correlation of anticCK13-1 antibody levels
with anti-cTNC5 antibody levels. In the same cohort,
antibodies to CEP-1, cFIBb, cVIM, cTNC5, and CCP-2
were also elevated, with cFIBb having the best
diagnostic sensitivity (66%) of the ACPA fine specifici-
ties, and CCP-2 exhibiting the highest levels overall
(85%) (Table 2). AnticCK13-1 antibody levels corre-
lated most strongly with anti-cTNC5 antibody levels (r
= 0.60, P < 0.001) and only moderately with other anti-
body levels (r = 0.30 for cFIBb, r = 0.42 for cVIM, r =
0.36 for CEP-1, and r = 0.30 for CCP-2; all P < 0.001)
(Figure 1A). There was a strong overlap between
cTNC5 and cCK13-1 positivity, as 88% of patients who
were positive for cCK13-1 were also positive for
cTNC5. There was only a partial overlap between
patients who were positive for cCK13-1 and those who
were positive for CEP-1, as only 55% of patients who
were positive for cCK13-1 were also CEP-1 positive
(Figure 1B).
To examine epitope specificity and potential
cross-reactivity of anti–cCK13-1 antibodies with other
antigens targeted by ACPAs, inhibition experiments
were performed with CEP-1, cFIBb, cTNC5, and
cVIM. Adsorption by the homologous peptide was effi-
cient for cCK13-1. There was no cross-reactivity
Table 1. Citrullinated CK-13 peptides identified in GCF from healthy controls, patients with both PD and RA, patients with PD
only, and patients with RA only*
Citrullinated CK-13 peptide Control (n = 2) PD and RA (n = 3) PD (n = 2) RA (n = 1)
5LQSSSASYGGGFGGGSCQLGGG(cit)GVSTCSTR35† 1 0 0 0
326RTLQGLEIELQSQLSMKAGLENTVAETEC(cit)355‡ 1 0 0 0
407SLLEGQDAKMIGFPSSAGSVSP(cit)R430† 1 0 0 0
430STSVTTTSSASVTTTSNASG(cit)R451†‡ 1 1 2 0
451(cit)TSDV(cit)RP458†‡ 1 2 1 0
451(cit)TSDVR(cit)P458†‡ 1 2 1 0
452TSDV(cit)RP458‡ 1 1 1 1
452TSDVR(cit)P458‡ 1 1 0 0
* Values are the number of patients. CK-13 = cytokeratin 13; PD = periodontitis; RA = rheumatoid arthritis.
† Gingival crevicular fluid (GCF) with no tryptic digest.
‡ Tryptic digest of GCF solution.
Table 2. Frequency of ACPA positivity in 287 RA patients*
Antigen Peptide sequence
Percent
of patients
cCK13-1 444TSNASGR-cit-TSDV-cit-RP458 24.0
cCK13-2 444TSNASGR-cit-TSDVR-cit-P458 0
cFIBb 36NEEGFFSA-cit-GHRPLDKK52 66.2
cTNC5 2176EHSIQFAEMKL-cit-PSNF-cit-NLEG-cit-
cit-KR2200
50.5
CEP-1 5KIHA-cit-EIFDS-cit-GNPTVE21 39.4
cVIM 59VYAT-cit-SSAV-cit-L-cit-SSVP74 32.1
CCP-2 – 84.5
* Antibody sensitivity was 98% for all protein antigens. ACPA = anti–
citrullinated peptide antibody; RA = rheumatoid arthritis; cCK13-1 =
citrullinated cytokeratin 13–derived peptide 1; cFIBb = citrullinated
fibrinogen b; cTNC5 = citrullinated tenascin-C; CEP-1 = citrullinated
a-enolase peptide 1; cVIM = citrullinated vimentin; CCP-2 = cyclic
citrullinated peptide 2.
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between anticCK13-1 and cTNC5, and only limited
cross-reactivity between anti–cCK13-1 and cFIBb (1 of
4 sera exhibiting cross-reactivity). There was some
cross-reactivity between anti–cCK13-1 and CEP-1 (2 of
4 sera exhibiting inhibition levels up to 57%) and with
anti-cVIM in particular, with 3 of 4 sera exhibiting inhi-
bition levels >65% (Figure 2). However, cCK13-1
showed no sequence homology with either peptide
(Table 2).
Association of ACPAs with RA risk factors and
with PD pathogens. We analyzed how cCK13-1 anti-
body positivity associated with the RA risk factors
smoking, shared epitope, and PD, in comparison to
other established ACPA fine specificities. Specific
ACPAs were associated with smoking (cFIBb [P =
0.001] and CEP-1 [P = 0.034]) and the shared epitope
(cVIM [P < 0.001] and CEP-1 [P = 0.001]) (Table 3).
Anti-cFIBb antibodies were associated with PD
(Table 3), and CCP-2, CEP-1, and cFIBb antibody
levels were significantly elevated in RA patients with
PD compared to RA patients without PD (Supplemen-
tary Figure 2).
We also determined the association of ACPA fine
specificities with infection with periodontal pathogens.
CEP-1–positive patients and cTNC5-positive patients
had higher serum levels of P gingivalis outer membrane
antibody compared to antibody-negative patients (P =
0.022 for CEP-1 and P = 0.015 for cTNC5), but no other
ACPAs were associated with P gingivalis outer mem-
brane antibody. None of the ACPA specificities were
Figure 1. A, Spearman’s rank correlation coefficients for the correlations between different anticitrullinated peptide antibodies (ACPAs) in
rheumatoid arthritis (RA) patients. P < 0.001 for all correlations. Boldface indicates the correlation between citrullinated cytokeratin 13 (cCK13-
1) and citrullinated tenascin-C (cTNC5) antibody levels. B, Venn diagrams showing the overlap between cTNC5, cCK13-1, and cyclic citrullinated
peptide 2 (CCP-2) antibody responses (left) and between cTNC5, cCK13-1, and citrullinated a-enolase peptide 1 (CEP-1) responses (right). Values
in the diagrams are the number of patients in each subset, and values in parentheses are the total number of ACPA-positive patients. cFIBb =
citrullinated fibrinogen b; cVIM = citrullinated vimentin.
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associated with P gingivalis DNA detected by PCR in
subgingival plaques. Patients who were positive for
cTNC5 and those who were positive for cCK13-1 had
significantly higher levels of antiP intermedia antibodies
(P = 0.001 for cTNC5 and P = 0.05 for cCK13-1)
(Table 4). This association was confirmed by statistically
significant quantitative correlations of both anti-cTNC5
and anticCK13-1 levels with levels of antiP interme-
dia antibodies (r = 0.207, P = 0.0004 for cTNC5 in all
RA patients; r = 0.223, P = 0.0005 for cTNC5 in CCP+
RA patients; r = 0.152, P = 0.010 for cCK13-1 in all RA
patients; and r = 0.161, P = 0.012 for cCK13-1 in CCP+
RA patients).
Anti-RgpB antibodies have been reported to be
significantly elevated in PD (31,35). We confirmed
these observations in our study, where anti-RgpB levels
in PD patients were increased compared to those in
patients without PD (mean  SD 0.53  0.54 lg/ml
versus 0.34  0.44 lg/ml; P < 0.0001) (Supplementary
Figure 3A, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40227/abstract). Moreover, anti-RgpB levels correlated
with antiP gingivalis outer membrane antibody levels
(r = 0.458, P < 0.001), and were associated with PD dis-
ease status (P = 0.001) as well as detection of P gingivalis
Figure 2. Anti–citrullinated cytokeratin 13 (anti–cCK13-1) antibody cross-reactivity with citrullinated tenascin-C (cTNC5), citrullinated fibrinogen
b (cFIBb), citrullinated a-enolase peptide 1 (CEP-1), and citrullinated vimentin (cVIM). Serum from patients positive for both anti–cCK13-1 and
the test antibodies were preincubated with increasing concentrations of the indicated test peptide, and the IgG responses to cCK13-1 were mea-
sured by enzyme-linked immunosorbent assay and presented as the OD. Each symbol represents an individual patient.
Table 3. Association of antibodies with risk factors for RA*
Risk factor
Smoking history
HLA
DRB1 SE
positive PD
Never
smoked
Former
smoker
Current
smoker
CCP-2+ (n = 240) 37 43 21 81 37
CCP-2 (n = 44) 45 48 7 49 23
P – – 0.076 <0.001† 0.085†
cFIBb+ (n = 190) 35 39 25 79 41
cFIBb (n = 97) 42 51 7 69 24
P – – 0.001 0.061 0.005
cVIM+ (n = 92) 39 41 20 92 36
cVIM (n = 195) 37 44 19 68 34
P – – 0.902 <0.001 0.802
CEP-1+ (n = 95) 27 48 24 88 41
CEP-1 (n = 192) 43 41 17 69 32
P – – 0.034 0.001 0.12
cTNC5+ (n = 145) 35 43 22 80 37
cTNC5 (n = 142) 40 44 16 71 33
P – – 0.412 0.085 0.539
cCK13-1+ (n = 69) 42 35 23 72 38
cCK13-1 (n = 218) 36 46 18 77 34
P – – 0.256 0.451 0.57
* Values are the percent of patients. Except where indicated
otherwise, chi-square tests were used to compare frequency distribu-
tions of categorical variables. RA = rheumatoid arthritis; SE = shared
epitope; PD = periodontitis; CCP-2 = cyclic citrullinated peptide 2;
cFIBb = citrullinated fibrinogen b; cVIM = citrullinated vimentin;
CEP-1 = citrullinated a-enolase peptide 1; cTNC5 = citrullinated
tenascin-C; cCK13-1 = citrullinated cytokeratin 13–derived peptide 1.
† By Fisher’s exact test.
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DNA by PCR (P = 0.005) (Supplementary Table 3).
However, anti-RgpB levels were slightly lower in RA
patients compared to OA patients (mean  SD 0.44 
0.50 lg/ml versus 0.36  0.45 lg/ml; P = 0.0353), and
there was no difference in anti-RgpB levels between
CCP-2–positive patients and CCP-2–negative patients
(mean  SD 0.34  0.46 lg/ml versus 0.35  0.44 lg/ml;
P = 0.4988) (Supplementary Figures 3B and C). In addi-
tion, RgpB levels did not differ between ACPA-negative
and ACPA-positive subsets (Table 4).
DISCUSSION
In this study, by analysis of the citrullinome of
GCF and of periodontal tissue, we identified an overlap
between periodontal citrullinated peptides and citrulli-
nated peptides that are recognized by autoantibodies in
RA. This included a previously unreported modified
peptide of CK-13 (cCK13-1), which we detected in gin-
gival fluid, and which exhibited elevated antibody
responses in patients with RA. Comparing anti–cCK13-1
antibody levels with levels of other well-established
ACPAs in RA revealed that 2 different sets of antibody
fine specificities exist that are differentially associated
with RA risk factors.
Previous studies demonstrated the presence of
citrullinated proteins in inflamed periodontal tissue by
immunohistochemical staining (14,15). However, that
approach cannot reveal the identity of these proteins.
Using mass spectrometry, we identified several citrulli-
nated peptides in GCF and periodontal tissue. Notably,
a number of citrullinated residues that we detected in
periodontal samples have previously been identified in
synovial fluid from RA patients (R35 in fibrinogen a
[32], R715 in a2-macroglobulin, R450 and R304 in
vimentin, and R93 in histone H2B type 2-E [33]). In
addition, we detected peptides with citrullinated resi-
dues at position R4 in histone 2A as well as at posi-
tions R69 and R71 in vimentin, that are described as
autoantibody targets in RA (29,34). Citrulline 71 in
vimentin was also recently detected in lung tissue sam-
ples, including those from smokers and patients with
chronic obstructive pulmonary disease (27).
Our GCF citrullinome shares some commonali-
ties with the findings in the study by Konig et al (17),
who also identified citrullinated peptides of histone 2A
and cytokeratin type II in GCF from PD patients.
There are also many differences between the studies,
which is perhaps not surprising given the nature of
mass spectrometry analysis and the small number of
samples examined. However, the findings of both stud-
ies are consistent with an emerging consensus that
citrullination occurs in samples from healthy subjects,
with an increase in the range of substrates and extent
Table 4. Periodontal pathogen status based on antibody positivity*
Periodontal
pathogen
Pg positive
by PCR,
% of patients
Anti-Pg outer membrane
antibody levels,
mean  SD lg/ml
Anti-RgpB at OD450,
mean  SD lg/ml
Anti-Pi outer membrane
antibody levels,
mean  SD lg/ml
Anti-Fn outer
membrane antibody
levels, mean  SD lg/ml
CCP-2+ (n = 240) 61 106  90 0.3  0.4 145  76 111  115
CCP-2 (n = 44) 61 96  84 0.3  0.5 146  93 96  74
P 1.000† 0.365‡ 0.495‡ 0.564‡ 0.308‡
cFIBb+ (n = 190) 64 112  93 0.4  0.5 150  79 113  124
cFIBb (n = 97) 56 94  81 0.3  0.5 137  79 97  72
P 0.195 0.108‡ 0.191‡ 0.109‡ 0.229‡
cVIM+ (n = 92) 65 114  101 0.3  0.4 154  85 120  164
cVIM (n = 195) 60 102  84 0.4  0.5 142  76 102  70
P 0.37 0.508‡ 0.604‡ 0.247‡ 0.979‡
CEP-1+ (n = 95) 67 122  98 0.4  0.5 156  81 122  158
CEP-1 (n = 192) 59 98  84 0.3  0.5 141  78 101  73
P 0.21 0.022‡ 0.221‡ 0.105‡ 0.297‡
cTNC5+ (n = 145) 67 118  96 0.4  0.4 160  78 118  135
cTNC5 (n = 142) 56 93  81 0.3  0.5 131  78 97  73
P 0.068 0.015 0.212‡ 0.001 0.109‡
cCK13-1+ (n = 69) 68 120  99 0.4  0.4 161  81 137  183
cCK13-1 (n = 218) 60 101  86 0.3  0.5 141  78 98  69
P 0.231 0.197‡ 0.230‡ 0.050‡ 0.078‡
* Except where indicated otherwise, chi-square tests were used to compare frequency distributions of categorical variables. Pg = Porphy-
romonas gingivalis; PCR = polymerase chain reaction; anti-RgpB = anti–R gingipain type B; anti-Pi = anti–Prevotella intermedia; anti-Fn =
anti–Fusobacterium nucleatum; CCP-2 = cyclic citrullinated peptide 2; cFIBb = citrullinated fibrinogen b; cVIM = citrullinated vimentin;
CEP-1 = citrullinated a-enolase peptide 1; cTNC5 = citrullinated tenascin-C; cCK13-1 = citrullinated cytokeratin 13–derived peptide 1.
† By Fisher’s exact test.
‡ By t-tests and Wilcoxon’s rank sum test.
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of protein citrullination in tissues that are more
severely inflamed (27,36,37). This, in turn, supports the
hypothesis that up-regulation of citrullination by
inflammation takes part in driving the ACPA response.
Our analysis also identified unique citrullinated
proteins not described so far. Two of these peptides
(cCK13-1 and cCK13-2), derived from CK-13, were ana-
lyzed in more detail. CK-13 is an intermediate filament
protein that is expressed in the gastrointestinal tract, sali-
va, and oral mucosa, but not in skin (The Human Protein
Atlas [http://www.proteinatlas.org] and Proteomics DB
[http://www.proteomicsdb.org]), suggesting that detection
of these peptides was not due to contamination of mass
spectrometry samples. No antibodies recognizing cCK13-2
were detected; however, 24% of RA patients had
ACPAs against cCK13-1 (antibody specificity 98%).
Both peptides share the same sequence, differing only
in the position of one citrullinated arginine residue,
underlining the importance of the neighboring amino
acids for the specificity of the antibody response. The
reactivity toward cCK13-1 was lower than that toward
other ACPA antigens, such as cFIBb, CEP-1, cVIM,
and cTNC5, but was citrulline-specific as no enhanced
antibody reactivity against the arginine control peptide
was detected in RA sera, and 99% of patients who were
positive for cCK13-1 were also positive for CCP-2.
Data in Figure 2 indicate that combined analysis
of anticCK13-1 antibodies with other antibody sub-
types, for example anti–CEP-1, would increase sensitiv-
ity, although any benefit gained would likely be offset
by a reduction in specificity. Although no cross-reactiv-
ity between anticCK13-1 antibodies and cTNC5 was
observed, cCK13-1 antibody levels correlated well with
cTNC5 antibody levels, and almost all RA patients who
were positive for cCK13-1 were also positive for
cTNC5. In addition, both cTNC5 and cCK13-1 peptide
sequences lie close to the C-terminal end of their cor-
responding protein, making it intriguing to speculate
that both peptides may be generated by a common
mechanism or target enzyme.
Citrullinated CK-13 was only detected in GCF,
and not in PD tissue. Differences in the citrullinome of
GCF and PD tissue may arise from underlying biologic
variation between the 2 sites. For example, CK-13 is
predominantly expressed in noncornified stratified
epithelia such as mucosal membranes, but levels are
most abundant in saliva, where it is found at levels 3–6
orders of magnitude higher than in tissues (Proteomics
DB). Soluble CK-13 in GCF may also exhibit greater
accessibility to PADs than that constrained or masked
within cells or within tissue. Proteomics analysis of
tissue and fluid also each face distinct technical
challenges, for example, sample dilution, varying
dynamic ranges of protein abundance, and ease of pro-
tein isolation, which may account for differences in
peptide profiles detected at each site. Finally, analysis
of a single tissue sample precludes generalization that
cCK13 is not formed in inflamed periodontal tissue.
Despite finding cCK13-1 in patients with PD
alone, or with coexisting RA and PD, and not in RA
patients without PD, larger sample sizes are required
to determine if this antigen arises specifically in GCF
during PD. The lack of association of anticCK13-1
antibodies with PD suggests that while GCF may pro-
vide a rich source of cCK13-1, it is not the only source
of this antigen. Indeed, CK-13 is also expressed in the
lung and gut (Proteomics DB), which raises the intrigu-
ing possibility that citrullination of this peptide in the
mucosal epithelia of these organs may also link dysbio-
sis at these sites with autoantibody generation in RA.
Taken together, these data demonstrate that
citrullination occurs in periodontal tissue in patients
with PD and that these citrullinated peptides can serve
as autoantigens in RA, suggesting that citrullinated pro-
teins generated in extraarticular tissues such as the
inflamed periodontium may play a role in breaching
tolerance in RA.
Because of the small number of GCF samples, it
was not possible to analyze whether the frequency of
citrullination is higher in patients with PD and/or RA
compared to healthy controls. However, little citrullina-
tion has been reported in GCF from healthy subjects,
compared to proteins in GCF from PD patients, which
are heavily citrullinated (17). In our study, we detected
citrullinated peptides in GCF from healthy controls.
Citrullination is often associated with inflammation (37),
but low levels of protein citrullination have also been
reported in tissue from healthy lungs, lymph nodes,
skeletal muscle, and kidney (27). We predominantly
detected internally citrullinated peptides, suggesting that
these peptides were citrullinated by the action of
endogenous human PADs (36,38), and not by PPAD,
which preferentially citrullinates C-terminal arginines
(18,19,39). These findings are consistent with those of a
previous study that identified only peptides with endo-
citrullination in GCF samples from PD patients (17).
Environmental and genetic risk factors are
involved in driving the autoimmune response toward
citrullinated peptides (40–42). As described previously
(43), we found that CEP-1 and cVIM were associated with
the HLADRB1 shared epitope, and cFIBb and CEP-1
were associated with smoking. We previously reported
that cTNC5 antibodies were significantly associated with
HLADRB1 shared epitope status (7), and here we
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describe a close to significant association (P = 0.085).
Although we observed no correlation of cVIM with
smoking, in contrast to other studies (43), the lack of
association of cTNC5 with smoking is consistent with data
from other cohorts showing weak (7) or no (44) links to
smoking for this ACPA subset. Neither of these RA risk
factors were associated with cCK13-1 antibodies. These
data demonstrate that ACPA fine specificities are differ-
entially associated with environmental and genetic RA
risk factors, which in some cases are stronger than associa-
tions observed with CCP-2.
The cFIBb antibodies were associated with PD
in general, while anti–CEP-1 and anti–cTNC5 were cor-
related with antiP gingivalis outer membrane antibod-
ies. However, we observed no association of these
antibodies with PCR-based detection of subgingival P
gingivalis. Although CEP-1 has previously been dis-
cussed as a candidate autoantigen involved in the etiol-
ogy of RA, since antibodies to citrullinated P gingivalis
a-enolase cross-react with antibodies to CEP-1 and
therefore may be involved in breaching tolerance in RA
(45), this is the first study to link ACPA reactivities with
other periodontal pathogens. Intriguingly, both cTNC5
and cCK13-1 were associated with antibodies reactive
with P intermedia. Although the correlations were weak
numerically, the statistical associations were highly sig-
nificant. Relatively small correlations with significant P
values are common for the sample size of the cohort
examined here, and while a small correlation does not
mean that the 2 variables are not related, it does mean
that most (but not all) of the value of one variable is
not determined by the value of the other variable.
These data therefore provide supporting evidence of
linked pathologic processes, but also suggest that addi-
tional contributing factors underlie disease pathology.
Infection with P intermedia, unlike P gingivalis,
does not exacerbate collagen-induced arthritis (46),
and, given that P intermedia does not express a PAD,
this suggests that infection with this bacterium may
drive the generation of distinct ACPA fine specificities
in a manner quite different from P gingivalis. For exam-
ple, it may facilitate human PAD activity in the peri-
odontium through induction of local inflammation.
Activated neutrophils are suggested as a source of
citrullinated antigens (47) and a recent publication
demonstrated how nucleases from P intermedia can
degrade neutrophil extracellular traps, which could lead
to increased periodontal pathogenicity (48) and release
of endogenous PADs (49). A recent study also demon-
strated that Aggregatibacter actinomycetemcomitans, but
not P gingivalis, F nucleatum, or P intermedia, could
induce citrullination of intracellular proteins in
neutrophils, and that antibodies against A actino-
mycetemcomitans are associated with citrullinated intra-
cellular proteins but not citrullinated extracellular
proteins (17). Taken together, these data demonstrate
that infection with different periodontal pathogens may
drive the generation of different ACPA fine specifici-
ties.
Anti-RgpB antibody levels, used as an additional
marker for P gingivalis infection as in previous publica-
tions (35,50,51), correlated well with antiP gingivalis
antibody levels and were significantly higher in RA
patients with PD than in RA patients without PD.
However, we observed no association between any
ACPA and these antibodies. In contrast to previous
studies in 2 well-documented Swedish cohorts, we
observed no association of anti-RgpB with CCP-2–posi-
tive RA, nor did we observe elevated anti-RgpB levels
in RA patients compared to OA patients, or in CCP-2–
positive RA patients compared to CCP-2–negative RA
patients (35,51). Our data are consistent with previous
studies showing no association of anti-RgpB antibodies
with RA or pre-RA (31,50) and no difference in anti–P
gingivalis outer membrane antibody levels between RA
and non-RA cohorts (12). Our findings were also con-
sistent with a previous study that showed that anti–P
gingivalis antibody levels were lower, though not signifi-
cantly, in RA patients than in subjects without RA
(52). These different results may be due to differences
in the cohorts analyzed, for example, differences in dis-
ease duration and severity, methods of antibody mea-
surement used, the age and sex of the population
studied, or, perhaps most importantly, the use of
healthy control groups versus the OA comparator
group used here.
In summary, our study has identified 2 groups of
ACPA fine specificities, each associated with different
environmental and genetic RA risk factors. Antibodies
to a novel peptide, cCK13-1, correlated strongly with
anti-cTNC5, both of which were linked to a serologic
response to infection with the periodontal pathogen P
intermedia. The second group, comprising antiCEP-1,
anti-cFIBb, and anti-cVIM, was predominantly associ-
ated with smoking and the shared epitope, consistent
with the findings of previous studies. The identification
of further distinct ACPA fine specificities, and the anal-
ysis of ACPA subsets in the context of the complex
changes that occur in the oral microbiota during PD,
will likely reveal further etiologic subsets of RA. This
information will be important in helping understand
different mechanisms by which tolerance can be brea-
ched to drive autoimmunity in this heterogeneous
disease.
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